Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v16-FR Version v13-FR
Language French French
Date Updated 2022-02-16 2021-12-01
Drug Identification Number 02406772 02406772
Brand name PMS-CYTARABINE PMS-CYTARABINE
Common or Proper name CYTARABINE CYTARABINE
Company Name PHARMASCIENCE INC PHARMASCIENCE INC
Ingredients CYTARABINE CYTARABINE
Strength(s) 100MG 100MG
Dosage form(s) SOLUTION SOLUTION
Route of administration SUBCUTANEOUS INTRAVENOUS INTRATHECAL SUBCUTANEOUS INTRAVENOUS INTRATHECAL SUBCUTANEOUS INTRAVENOUS INTRATHECAL SUBCUTANEOUS INTRAVENOUS INTRATHECAL
Packaging size 2000mg/20mL 2000mg/20mL
ATC code L01BC L01BC
ATC description ANTIMETABOLITES ANTIMETABOLITES
Reason for shortage Disruption of the manufacture of the drug. Disruption of the manufacture of the drug.
Anticipated start date 2022-01-04 2022-01-04
Actual start date
Estimated end date 2022-02-25 2022-02-25
Actual end date 2022-02-15
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments Limited supply. Anticipated BO from January 4, 2022 to February 25, 2022 Limited supply. Anticipated BO from January 4, 2022 to February 25, 2022
Health Canada comments